Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences (NASDAQ:XBIO) has expanded its research collaboration with The Scripps Research Institute to advance its DNase platform development. The company's systemic DNase I candidate, XBIO-015, is being developed in combination with CAR-T cell therapy for both hematologic and solid tumors.
Studies have demonstrated that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and extends survival compared to CAR-T cell therapy alone. The research program will now include additional models of lymphoma and leukemia to further validate these findings.
The DNase-based platform targets neutrophil extracellular traps (NETs) in the tumor microenvironment, with preclinical data showing improved efficacy of various cancer treatments. The company is advancing towards Phase 1 clinical development for pancreatic carcinoma and other advanced solid tumors.
Xenetic Biosciences (NASDAQ:XBIO) ha ampliato la sua collaborazione di ricerca con The Scripps Research Institute per far progredire lo sviluppo della sua piattaforma DNase. Il candidato sistemico DNase I dell'azienda, XBIO-015, viene sviluppato in combinazione con la terapia con cellule CAR-T per tumori ematologici e solidi.
Gli studi hanno dimostrato che la somministrazione combinata di DNase I con le cellule CAR-T riduce significativamente il carico tumorale, diminuisce le lesioni metastatiche e prolunga la sopravvivenza rispetto alla sola terapia con cellule CAR-T. Il programma di ricerca includerà ora ulteriori modelli di linfoma e leucemia per convalidare ulteriormente questi risultati.
La piattaforma basata su DNase mira a neutralizzare le trappole extracellulari dei neutrofili (NETs) nel microambiente tumorale, con dati preclinici che mostrano un miglioramento dell'efficacia di vari trattamenti oncologici. L'azienda sta avanzando verso lo sviluppo clinico di Fase 1 per il carcinoma pancreatico e altri tumori solidi avanzati.
Xenetic Biosciences (NASDAQ:XBIO) ha ampliado su colaboración de investigación con The Scripps Research Institute para avanzar en el desarrollo de su plataforma DNase. El candidato sistémico DNase I de la compañía, XBIO-015, se está desarrollando en combinación con la terapia con células CAR-T para tumores hematológicos y sólidos.
Los estudios han demostrado que la coadministración de DNase I con células CAR-T reduce significativamente la carga tumoral, disminuye las lesiones metastásicas y prolonga la supervivencia en comparación con la terapia con células CAR-T sola. El programa de investigación incluirá ahora modelos adicionales de linfoma y leucemia para validar aún más estos hallazgos.
La plataforma basada en DNase apunta a las trampas extracelulares de neutrófilos (NETs) en el microambiente tumoral, con datos preclínicos que muestran una mayor eficacia de varios tratamientos contra el cáncer. La compañía avanza hacia el desarrollo clínico de Fase 1 para carcinoma pancreático y otros tumores sólidos avanzados.
Xenetic Biosciences (NASDAQ:XBIO)는 DNase 플랫폼 개발을 촉진하기 위해 The Scripps Research Institute와의 연구 협력을 확대했습니다. 회사의 전신 DNase I 후보물질인 XBIO-015는 혈액암 및 고형암 모두에 대해 CAR-T 세포 치료와 병용하여 개발 중입니다.
연구 결과 DNase I과 CAR-T 세포의 병용 투여가 종양 부담을 크게 줄이고, 전이 병변을 감소시키며, 단독 CAR-T 세포 치료에 비해 생존 기간을 연장한다는 것이 입증되었습니다. 연구 프로그램은 이러한 결과를 추가로 검증하기 위해 림프종 및 백혈병의 추가 모델을 포함할 예정입니다.
DNase 기반 플랫폼은 종양 미세환경 내 중성구 세포외 덫(NETs)을 표적으로 하며, 전임상 데이터는 다양한 암 치료제의 효능 향상을 보여줍니다. 회사는 췌장암 및 기타 진행성 고형암에 대해 1상 임상 개발을 진행 중입니다.
Xenetic Biosciences (NASDAQ:XBIO) a élargi sa collaboration de recherche avec The Scripps Research Institute pour faire progresser le développement de sa plateforme DNase. Le candidat systémique DNase I de la société, XBIO-015, est développé en combinaison avec la thérapie par cellules CAR-T pour les tumeurs hématologiques et solides.
Des études ont montré que la co-administration de DNase I avec les cellules CAR-T réduit significativement la charge tumorale, diminue les lésions métastatiques et prolonge la survie par rapport à la thérapie par cellules CAR-T seule. Le programme de recherche inclura désormais des modèles supplémentaires de lymphome et de leucémie pour valider davantage ces résultats.
La plateforme basée sur la DNase cible les pièges extracellulaires des neutrophiles (NETs) dans le microenvironnement tumoral, avec des données précliniques montrant une amélioration de l'efficacité de divers traitements contre le cancer. La société progresse vers un développement clinique de phase 1 pour le carcinome pancréatique et d'autres tumeurs solides avancées.
Xenetic Biosciences (NASDAQ:XBIO) hat seine Forschungskooperation mit dem The Scripps Research Institute erweitert, um die Entwicklung seiner DNase-Plattform voranzutreiben. Der systemische DNase I-Kandidat des Unternehmens, XBIO-015, wird in Kombination mit CAR-T-Zelltherapie für hämatologische und solide Tumoren entwickelt.
Studien haben gezeigt, dass die gleichzeitige Verabreichung von DNase I mit CAR-T-Zellen die Tumorlast signifikant reduziert, metastatische Läsionen verringert und das Überleben verlängert im Vergleich zur alleinigen CAR-T-Zelltherapie. Das Forschungsprogramm wird nun zusätzliche Modelle von Lymphomen und Leukämien umfassen, um diese Ergebnisse weiter zu validieren.
Die DNase-basierte Plattform zielt auf neutrophile extrazelluläre Fallen (NETs) im Tumormikromilieu ab, wobei präklinische Daten eine verbesserte Wirksamkeit verschiedener Krebstherapien zeigen. Das Unternehmen schreitet in Richtung klinischer Phase-1-Entwicklung für Pankreaskarzinom und andere fortgeschrittene solide Tumoren voran.
- Preclinical studies show significant reduction in tumor burden and metastatic lesions
- DNase I combination therapy demonstrates markedly extended survival rates
- Platform shows potential to enhance multiple cancer treatment modalities
- Advancing towards Phase 1 clinical trials for pancreatic cancer
- Still in preclinical stage with no human trial data yet
- Requires further validation through additional research models
Insights
Xenetic's expanded DNase research with Scripps builds on promising preclinical cancer data that could enhance CAR-T efficacy.
Xenetic Biosciences has expanded its collaboration with The Scripps Research Institute to further develop its DNase platform technology, which shows promise in enhancing CAR-T cell therapy efficacy. This is a meaningful development in immuno-oncology with potential implications for treating both blood cancers and solid tumors.
The company's lead candidate, XBIO-015, targets neutrophil extracellular traps (NETs) - web-like structures that contribute to immunosuppression in the tumor microenvironment. Preclinical studies have demonstrated that combining DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and extends survival compared to using CAR-T cells alone.
The expanded collaboration will now include additional models of lymphoma and leukemia to further validate these findings. This approach addresses a critical limitation in current CAR-T therapy - the immunosuppressive tumor microenvironment that often restricts T-cell infiltration and function.
The mechanism is particularly interesting: DNase I degrades the NETs, which appears to enhance CAR-T cell infiltration into tumors while simultaneously reducing immunosuppression. The company is advancing this technology toward Phase 1 clinical trials for pancreatic carcinoma and other advanced solid tumors.
This platform technology could potentially address a significant unmet need, as current CAR-T therapies have shown limited efficacy in solid tumors despite their success in certain blood cancers. The ability to improve CAR-T cell infiltration and function could extend the utility of these therapies to a broader range of cancer types.
Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date
FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has continued its collaboration with The Scripps Research Institute ("TSRI") to advance the development of the Company's development program evaluating the combination of systemic DNase I and CAR T-cell therapies.
Xenetic's systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy for both hematologic and solid tumors. Studies conducted at TSRI using lymphoma and metastatic melanoma models have shown that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and markedly extends survival compared to CAR-T cell monotherapy. Importantly, systemic DNase I-mediated degrading of neutrophil extracellular traps (NETs) enhances CAR-T cell efficacy increasing the infiltration of both CAR-T cells and endogenous T cells into tumors and by mitigating the immunosuppressive tumor microenvironment (TME). Based on these promising results, the research program has been expanded to include additional models of lymphoma and leukemia to further validate these findings.
"We are pleased to further expand our collaboration with Scripps Research and explore the full potential of our DNase-based oncology platform. The data generated to date continues to be encouraging and we believe provides a compelling rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR-T cell therapy. We are grateful for the Scripps Research team and look forward to continuing to leverage their knowledge and expertise," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
Xenetic's DNase-based oncology platform is designed to target NETs, which are weblike structures composed of extracellular chromatin coated with histones and other proteins. In cancer, NETs are expelled by activated neutrophils into the TME and blood, thereby promoting cancer spread and local and systemic immunosuppression. Reduction of NETs burden via application of Xenetic's proprietary recombinant human DNase I has been shown to improve efficacy of immunotherapy, adoptive cell therapy and chemotherapy in preclinical animal models.
Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "making", and other words of similar meaning, including, but not limited to: continuing to leverage the knowledge and expertise of the team at Scripps to potentially expand and broaden the utility of our proprietary platform technology; and expectations regarding our DNase-based oncology platform, including statements regarding: advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications; focusing on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications; advancing the development of the Company's program on the combination of systemic DNase and CAR T-cell therapies; our belief that preclinical data that highlights the critical role of NETs in modulating CAR-T cell efficacy provides a compelling rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR-T cell therapy; plans to advance our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors; the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression; and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. All forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What is Xenetic Biosciences' XBIO-015 and how does it work with CAR-T therapy?
What are the key findings from Xenetic's (XBIO) DNase platform studies?
When will Xenetic Biosciences (XBIO) begin clinical trials for its DNase platform?
What types of cancer is Xenetic's DNase platform targeting?
How does Xenetic's collaboration with Scripps Research Institute impact their DNase platform development?
